TNF and juvenile idiopathic arthritis: The anti-TNF-α mAb biologics (etanercept and adalimumab) have both been shown to preferentially suppress Th17/Th1 cells and Th17 cell plasticity in vivo in juvenile idiopathic arthritis [69].